Significant prognostic cytogenetic risk groups in adults aged 60 years or older with acute myeloid leukemia (AML) identified by tree analysis for complete remission, disease-free survival and overall survival in a Cancer and Leukemia Group B study.*
| Cytogenetic Risk Groups . | No. . | Outcome, % (95% CI) . |
|---|---|---|
| * This research was originally published in Blood.9 Farag et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood . 2006 ;108 :63 –73 | ||
| Complete remission (CR: | CR rate: | |
| Complex karyotype with ≥ 3 aberrations | 122 | 25 (17–32) |
| Rare aberrations | 33 | 30 (15–46) |
| Non-complex ≥ 3, non-rare aberrations | 480 | 56 (51–60) |
| Disease-free survival: | 5-year DFS: | |
| Complex karyotype with ≥ 5 aberrations | 22 | 0 |
| Fewer than 5 aberrations | 286 | 9.1 (6.1–12.8) |
| Overall Survival: | 5-year OS: | |
| Complex karyotype with ≥ 5 aberrations | 94 | 0 |
| CBF AML | 31 | 19.4 (7.9–34.6) |
| Rare aberrations | 33 | 0 |
| Fewer than 5 non-CBF AML, non-rare aberrations | 477 | 7.5 (5.4–10.1) |
| Cytogenetic Risk Groups . | No. . | Outcome, % (95% CI) . |
|---|---|---|
| * This research was originally published in Blood.9 Farag et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood . 2006 ;108 :63 –73 | ||
| Complete remission (CR: | CR rate: | |
| Complex karyotype with ≥ 3 aberrations | 122 | 25 (17–32) |
| Rare aberrations | 33 | 30 (15–46) |
| Non-complex ≥ 3, non-rare aberrations | 480 | 56 (51–60) |
| Disease-free survival: | 5-year DFS: | |
| Complex karyotype with ≥ 5 aberrations | 22 | 0 |
| Fewer than 5 aberrations | 286 | 9.1 (6.1–12.8) |
| Overall Survival: | 5-year OS: | |
| Complex karyotype with ≥ 5 aberrations | 94 | 0 |
| CBF AML | 31 | 19.4 (7.9–34.6) |
| Rare aberrations | 33 | 0 |
| Fewer than 5 non-CBF AML, non-rare aberrations | 477 | 7.5 (5.4–10.1) |